Jewell Ward

Publications (2)16.29 Total impact

• Article: CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta.

  Dustin Baldridge, Ulrike Schwarze, Roy Morello, Jennifer Lennington, Terry K Bertin, James M Pace, Melanie G Pepin, Maryann Weis, David R Eyre, Jennifer Walsh, [......], Carl Lindman, Judith Martin, Jewell Ward, Emmanuelle Lemyre, John J Mitchell, Deborah Krakow, David L Rimoin, Daniel H Cohn, Peter H Byers, Brendan Lee
  [show abstract] [hide abstract]
  ABSTRACT: Autosomal dominant osteogenesis imperfecta (OI) is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen. Recently, dysregulation of hydroxylation of a single proline residue at position 986 of both the triple-helical domains of type I collagen alpha1(I) and type II collagen alpha1(II) chains has been implicated in the pathogenesis of recessive forms of OI. Two proteins, cartilage-associated protein (CRTAP) and prolyl-3-hydroxylase-1 (P3H1, encoded by the LEPRE1 gene) form a complex that performs the hydroxylation and brings the prolyl cis-trans isomerase cyclophilin-B (CYPB) to the unfolded collagen. In our screen of 78 subjects diagnosed with OI type II or III, we identified three probands with mutations in CRTAP and 16 with mutations in LEPRE1. The latter group includes a mutation in patients from the Irish Traveller population, a genetically isolated community with increased incidence of OI. The clinical features resulting from CRTAP or LEPRE1 loss of function mutations were difficult to distinguish at birth. Infants in both groups had multiple fractures, decreased bone modeling (affecting especially the femurs), and extremely low bone mineral density. Interestingly, "popcorn" epiphyses may reflect underlying cartilaginous and bone dysplasia in this form of OI. These results expand the range of CRTAP/LEPRE1 mutations that result in recessive OI and emphasize the importance of distinguishing recurrence of severe OI of recessive inheritance from those that result from parental germline mosaicism for COL1A1 or COL1A2 mutations.
  Human Mutation 07/2008; 29(12):1435-42. · 5.69 Impact Factor
• Article: Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene.

  Charles E Schwartz, Melanie M May, Nancy J Carpenter, R Curtis Rogers, Judith Martin, Martin G Bialer, Jewell Ward, Javier Sanabria, Silvana Marsa, James A Lewis, Roberto Echeverri, Herbert A Lubs, Kytja Voeller, Richard J Simensen, Roger E Stevenson
  [show abstract] [hide abstract]
  ABSTRACT: Allan-Herndon-Dudley syndrome was among the first of the X-linked mental retardation syndromes to be described (in 1944) and among the first to be regionally mapped on the X chromosome (in 1990). Six large families with the syndrome have been identified, and linkage studies have placed the gene locus in Xq13.2. Mutations in the monocarboxylate transporter 8 gene (MCT8) have been found in each of the six families. One essential function of the protein encoded by this gene appears to be the transport of triiodothyronine into neurons. Abnormal transporter function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood. Infancy and childhood in the Allan-Herndon-Dudley syndrome are marked by hypotonia, weakness, reduced muscle mass, and delay of developmental milestones. Facial manifestations are not distinctive, but the face tends to be elongated with bifrontal narrowing, and the ears are often simply formed or cupped. Some patients have myopathic facies. Generalized weakness is manifested by excessive drooling, forward positioning of the head and neck, failure to ambulate independently, or ataxia in those who do ambulate. Speech is dysarthric or absent altogether. Hypotonia gives way in adult life to spasticity. The hands exhibit dystonic and athetoid posturing and fisting. Cognitive development is severely impaired. No major malformations occur, intrauterine growth is not impaired, and head circumference and genital development are usually normal. Behavior tends to be passive, with little evidence of aggressive or disruptive behavior. Although clinical signs of thyroid dysfunction are usually absent in affected males, the disturbances in blood levels of thyroid hormones suggest the possibility of systematic detection through screening of high-risk populations.
  The American Journal of Human Genetics 08/2005; 77(1):41-53. · 10.60 Impact Factor